Navigation Links
Low-Dose HRT Patch May Lessen Stroke Risk
Date:6/4/2010

Study suggests that patches offer better odds than hormone therapy in pill form,,

FRIDAY, June 4 (HealthDay News) -- Getting low-dose hormone replacement therapy through a skin patch may reduce a woman's risk for stroke, but high-dose patches could actually raise the risk, a new study suggests.

Many women take hormone therapy to treat menopausal symptoms, but some studies have linked the treatment to an increased risk for stroke.

For the new study, researchers reviewed a British database of medical records from 1987 and 2006, focusing on 15,710 cases in which a woman between the ages of 50 and 79 had a stroke. They compared the women with 59,958 other women.

Women who used low-dose patches were at no greater risk for stroke than were women who didn't use patches, the study found, but use of high-dose patches upped the odds of stroke by 88 percent. Taking hormone therapy orally, meanwhile, increased the risk by 25 to 30 percent, compared with the risk for women who didn't take hormone replacement in pill form. Dosage and formulation -- whether the oral therapy was estrogen alone or in combination with progesterone -- were found to have no bearing on the results.

Taking hormone replacement pills for less than a year did not boost risk for stroke, according to the study, but the risk rose by 35 percent for women who took the pills for longer than a year.

The study authors cautioned that their research alone doesn't definitively prove that patches are healthier than pills.

The findings were published online June 4 in BMJ.

More information

The U.S. National Library of Medicine has more on hormone replacement therapy.



-- Randy Dotinga



SOURCE: BMJ, news release, Jun
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Low-Dose Platelet Transfusions Deemed Safe
2. NIH takes step to assess any possible risk associated with low-dose radiation exposure
3. TheBookPatch.com Launches: Writers Have Free Online Destination with Myriad Tools; Users Can Print One Book at a Time
4. Using Nicotine Patch Longer Boosts Efforts to Quit
5. More smokers kick the habit with extended nicotine patch therapy, Penn research shows
6. Mastery of physical goals lessens disease-related depression and fatigue
7. Age is a factor in choosing between two comparable stroke-prevention procedures
8. Ultrasound Helps Spot Stroke Risk in Symptomless Patients
9. Too Many Stroke Patients Go Without Statins
10. Landmark Clinical Trial Shows Surgery and Stenting Equally Safe and Effective at Preventing Stroke
11. Surgery, Stenting Fare Equally Well in Preventing Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... West Orange, NJ (PRWEB) , ... September 01, ... ... in the spine to eliminate chronic back pain – once required a long, ... with a shorter hospital stay, less pain, less blood loss and minimal muscle ...
(Date:8/31/2015)... ... 31, 2015 , ... Dental clinicians from Newcastle University, United ... to learn more about its integrated approach to diabetes care. , Philip Preshaw, ... Cellular Medicine at Newcastle University, and Susan Bissett, National Institute for Health Research ...
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... ... center management, recently opened registration for the company’s second Introduction to Hyperbaric Medicine ... held October 15-18, 2015 aboard the Queen Mary Hotel in Long Beach, CA. ...
(Date:8/31/2015)... Ohio (PRWEB) , ... August 31, 2015 , ... ... Michael as Vice President, Marketing and Corporate Communications. In this capacity, Michael will ... , CareSource is an industry leader in consumer-focused programs that have contributed to ...
(Date:8/31/2015)... , ... August 31, 2015 , ... In an ... the Plastic and Reconstructive Surgery Global Open Journal that discusses the future of 3-D ... discussed how, in the future, customized implants, prosthetics, and other 3-D printed tools could ...
Breaking Medicine News(10 mins):Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Western Diabetes Institute Collaborates with UK team 2Health News:Western Diabetes Institute Collaborates with UK team 3Health News:Western Diabetes Institute Collaborates with UK team 4Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3
... , ASHEVILLE, N.C. , Jan. ... and smart companies are working hard to adjust their recipes to find ... is one option that is all natural, low in sodium—40% to 70% ... the first and only natural low sodium sea salt. Total sales that ...
... , St. Jude Children,s Research Hospital scientists lead effort ... host of bacterial toxins , MEMPHIS, Tenn. , ... of widely used cholesterol-lowering drugs might help protect individuals from ... pose a deadly threat to those with sickle cell disease. ...
... Acknowledging that the idea of rationing health care, particularly at ... get much rational consideration, a Johns Hopkins emeritus professor of ... an opinion piece featured in this month,s issue of the ... article, John Freeman, M.D., Lederer Professor Emeritus of Pediatric Neurology ...
... from forming, research shows , TUESDAY, Jan. 19 (HealthDay News) ... tobacco known as NNK contributes to the formation of lung ... Taiwan report that NNK contributes to the accumulation of a ... DNMT1 turns off genes that keep tumors from forming. ...
... chromosome lineage reveals farming influence , TUESDAY, Jan. 19 (HealthDay ... farmers who migrated from the Near East 10,000 years ago, ... Y chromosome, which is passed from father to son. , ... by about 110 million men -- it follows a gradient ...
... ... ALS (amyotrophic laterals sclerosis) announced today that it has appointed Gordon S. LaVigne as ... ... ALS Association , the nation’s leader in the fight against the disease ALS ...
Cached Medicine News:Health News:Ocean's Flavor Natural Sea Salt is Helping Companies Reach Low Sodium Goals 2Health News:Ocean's Flavor Natural Sea Salt is Helping Companies Reach Low Sodium Goals 3Health News:Cholesterol-Lowering Drug Shows Promise Against Serious Infections in Sickle Cell Disease 2Health News:Cholesterol-Lowering Drug Shows Promise Against Serious Infections in Sickle Cell Disease 3Health News:Cholesterol-Lowering Drug Shows Promise Against Serious Infections in Sickle Cell Disease 4Health News:Cholesterol-Lowering Drug Shows Promise Against Serious Infections in Sickle Cell Disease 5Health News:Reasoning through the rationing of end-of-life care 2Health News:Gordon S. LaVigne Appointed ALS Association Chief Development and Communications Officer , 2Health News:Gordon S. LaVigne Appointed ALS Association Chief Development and Communications Officer , 3
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
Medicine Products: